Close Menu

mergers & acquisitions

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.

By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.

Cytena has developed a printer technology that allows single cell isolation for genomics research and clonal cell line development for biopharmaceutical production.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

The deals follow a pair of other recent acquisitions by Precision for Medicine in the artificial intelligence technology and biomarker analysis fields.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.